JANX - Janux Therapeutics, Inc. Stock Price, Fair Value and News

$56.83+0.08 (+0.14%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

JANX Price Action

Last 7 days

-7.0%

Last 30 days

16.1%

Last 90 days

13.2%

Trailing 12 Months

466.0%

JANX RSI Chart

JANX Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-49.27

Price/Sales (Trailing)

117.3

Price/Free Cashflow

-78.86

JANX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

JANX Fundamentals

JANX Revenue

Revenue (TTM)

25.4M

Rev. Growth (Yr)

83.35%

Rev. Growth (Qtr)

-1.02%

JANX Earnings

Earnings (TTM)

-60.5M

Earnings Growth (Yr)

-142.56%

Earnings Growth (Qtr)

-370.87%

JANX Profitability

Return on Equity

-9.23%

Return on Assets

-8.71%

Free Cashflow Yield

-1.27%

JANX Investor Care

Shares Dilution (1Y)

13.68%

Diluted EPS (TTM)

-1.15

JANX Alerts

1 major insider sales recently.
CITADEL ADVISORS LLC reported owning 1.9% of JANX [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	17.3M	21.9M	25.4M	0
2023	6.7M	9.6M	12.0M	14.7M
2022	3.4M	3.3M	3.9M	4.0M
2021	0	0	0	3.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Janux Therapeutics, Inc.

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.

CEO	Dr. David Alan Campbell Ph.D.
WEBSITE	januxrx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	67

Janux Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Janux Therapeutics, Inc.? What does JANX stand for in stocks?

JANX is the stock ticker symbol of Janux Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Janux Therapeutics, Inc. (JANX)?

As of Fri Dec 20 2024, market cap of Janux Therapeutics, Inc. is 2.98 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JANX stock?

You can check JANX's fair value in chart for subscribers.

Is Janux Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether JANX is over valued or under valued. Whether Janux Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Janux Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JANX.

What is Janux Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, JANX's PE ratio (Price to Earnings) is -49.27 and Price to Sales (PS) ratio is 117.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JANX PE ratio will change depending on the future growth rate expectations of investors.